You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 195971 - 195980 of 207712 results
  1. Topic 372: Development and Validation of Non- Mouse Reagents to Enable Preclinical Development of Novel Therapeutics

    SBC: AVANTGEN INC            Topic: NCI

    There is an increasing appreciation that dogs with naturally occurring cancers may be a better model system for evaluating cancer therapeutics than the traditional mouse model systems. However, use of dogs for evaluating the emerging class of immunotherapeutics for oncology is limited by the availability of suitable reagents to mentor the response of the canine immune system. The majority of reage ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. TOPIC 372:DEVELOPMENT AND VALIDATION OF NON-MOUSE REAGENTS TO ENABLE PRECLINICAL DEVELOPMENT OF NOVEL THERAPEUTICS

    SBC: AVANTGEN INC            Topic: 372

    Dogs with naturally occurring cancers can serve as a better model system for evaluating novel cancer immuno-therapeutics than the traditional mouse model systems, and also provide a target patient group. However, use of canine cancer patients is currently limited by the availability of suitable reagents to monitor canine immune responses. The majority of commercially-available reagents for canine ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. TOPIC 389- DEVELOPMENT OF A MACHINE LEARNING MODEL FOR PROSTATE CANCER TREATMENT PLANNING

    SBC: NICOLALDE R&D LLC            Topic: NCI

    This project s goal is to develop and test an application that uses Artificial IntelligenceAIto improve consistency and quality of RT treatment plans for prostate cancerBy understanding expert planner preferences in structure contouring and treatment planningand combining this rationale with data amassed in NRG clinical trialsAI models will be trained to produce contours and treatment plans achiev ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. TOPIC 45: DEVELOPMENT OF A SUICIDE PREVENTION TRAINING CURRICULUM FOR JUSTICE SYS

    SBC: POLICY RESEARCH ASSOCIATES INC            Topic: N/A

    N/A

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  5. TOPIC 45: DEVELOPMENT OF A SUICIDE PREVENTION TRAINING CURRICULUM FOR JUSTICE SYS

    SBC: POLICY RESEARCH ASSOCIATES INC            Topic: N/A

    This proposal provides for an enhancement of the Phase I core curriculum to include information on specific sociodemographic groups (women, minorities, elders, juveniles), issues relevant to myriad legal practice settings (domestic violence), and those suicides which leave a wake of pain and suffering for communities and families, murder-suicides. Furthermore, the curriculum will address the ethic ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  6. TOPIC 314: DEVELOPMENT OF HUMAN TISSUE CULTURE SYSTEM THAT MIMICS THE TUMOR MICRO

    SBC: HemoShear Therapeutics, LLC            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. TOPIC 403: DEVELOPMENT OF SPATIAL MICROPURIFICATION TECHNOLOGY

    SBC: AVONEAUX MEDICAL INSTITUTE, LLC            Topic: 403

    The tumor microenvironment (TME) comprises a mixture of cell types, including tumor cells, cancer sub-clones, metaplasia, dysplasia, desmoplasia, reactive fibroblasts, and a complex immune response. Measuring the molecular status of each cellular component within the TME is important to understanding tumor initiation and progression as well as in determining the interplay between cancer and normal ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Topic 372: Development of the Fully Humanized 9-in-9-out Rat Drug Metabolism-CYP450 Model, Using the Active Genetic: Gene Drive Technology

    SBC: SYNBAL INC            Topic: NCI

    In this Fast track SBIR grant we aim, by the end of Phase II, to prepare and commercialize a fully humanized rat with Knock-out of many rat drug metabolism related CYP450's (9-in-9-out Rat Drug Metabolism-CYP450 Model) and Knock-in of the human counterpart. IN PHASE I we will develop an Active Genes: Gene Drive (AG:GD) rat - a rat with a properly configured Cas9 to power Active Genetics (AG); AND, ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. TOPIC 229: DEV. OF MOLECULAR PHARMACODYNAMIC ASSAYS FOR TARGET

    SBC: BIOO SCIENTIFIC CORPORATION            Topic: N/A

    The research will result in new kits for quantitative detection and monitoring of hypoxia inducible factor-1 alpha (Hif-1a), a promising cellular target protein for pharmacological intervention. During the Phase 1 project, monoclonal antibodies will be developed and used to create highly sensitive ELISA assays for Hif-1a. Mice immunized with peptides derived from Hif-1a will be used to produce hyb ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Topic 369: DRUG DELIVERY SYSTEM TO SAVE HEARING DURING PEDIATRIC CHEMOTHERAPY REGIMENS

    SBC: Otomagnetics, Inc.            Topic: NCI

    Our company has invented a magnetic drug delivery device that we intend to develop to enable prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin chemotherapy regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing loss in kids has a dramatic impact on the ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government